Hester Biosciences Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported total revenue of INR 322.96 million compared to INR 292.79 million a year ago. Profit before tax was INR 109.26 million compared to INR 75.93 million a year ago. Profit for period was INR 65.01 million or INR 7.64 per basic and diluted share annualized compared to INR 58.21 million or INR 6.84 per basic and diluted share not annualized a year ago. EBITDA is achieved at 39.50% of total sales for third quarter of 2018 as against 32.39% in third quarter of fiscal year 2017. ROE was 18.99% against 20.24% a year ago. For the nine months, the company reported total revenue of INR 993.23 million compared to INR 906.13 million a year ago. Profit before tax was INR 342.67 million compared to INR 237.17 million a year ago. Profit for period was INR 215.44 million or INR 25.33 per basic and diluted share annualized compared to INR 178.29 million or INR 20.96 per basic and diluted share not annualized a year ago. EBITDA is achieved at 39.32% as against 32.66% in nine months ended 2017. ROE was 20.92% against 20.61% a year ago.